Journal
CANCER PREVENTION RESEARCH
Volume 4, Issue 7, Pages 994-1001Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-10-0301
Keywords
-
Categories
Funding
- AIRC [IG 5377]
- MIUR
- University of Turin
- Compagnia di San Paolo
- Fondazione CRT progetto Alfieri
- Regione Piemonte
- EU Consortium of Anticancer Antibody Development (EUCAAD) [200755]
- EU Community
Ask authors/readers for more resources
Vaccines against oncoantigens halt early neoplastic lesions in several cancer-prone, genetically engineered mouse models, whereas their ability to prevent chemical carcinogenesis has not been explored. This is a significant issue, as exposure to chemical mutagens is responsible for a substantial percentage of cancers worldwide. Here, we show that the archetypal oncoantigen ERBB2 is transiently overexpressed in Syrian hamsters during the early stages of 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced oral carcinogenesis. Repeated DNA vaccinations against ERBB2 significantly reduce the number, size, and severity of oral lesions in a manner directly proportional to the anti-ERBB2 antibody response. These results support the prospects of vaccines as a fresh strategy in the management of individuals at risk for exposure to defined carcinogenic agents. Cancer Prev Res; 4(7); 994-1001. (C)2011 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available